Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

Proteomic Screening and Lasso Regression Reveal Differential Signaling in Insulin and Insulin-like Growth Factor I (IGF1) Pathways.

Erdem C, Nagle AM, Casa AJ, Litzenburger BC, Wang YF, Taylor DL, Lee AV, Lezon TR.

Mol Cell Proteomics. 2016 Sep;15(9):3045-57. doi: 10.1074/mcp.M115.057729. Epub 2016 Jun 30.

2.

The estrogen receptor alpha nuclear localization sequence is critical for fulvestrant-induced degradation of the receptor.

Casa AJ, Hochbaum D, Sreekumar S, Oesterreich S, Lee AV.

Mol Cell Endocrinol. 2015 Nov 5;415:76-86. doi: 10.1016/j.mce.2015.08.007. Epub 2015 Aug 10. Erratum in: Mol Cell Endocrinol. 2016 Mar 15;424():129.

PMID:
26272024
3.

Forkhead box A1 (FOXA1) is a key mediator of insulin-like growth factor I (IGF-I) activity.

Potter AS, Casa AJ, Lee AV.

J Cell Biochem. 2012 Jan;113(1):110-21. doi: 10.1002/jcb.23333.

4.

Estrogen and insulin-like growth factor-I (IGF-I) independently down-regulate critical repressors of breast cancer growth.

Casa AJ, Potter AS, Malik S, Lazard Z, Kuiatse I, Kim HT, Tsimelzon A, Creighton CJ, Hilsenbeck SG, Brown PH, Oesterreich S, Lee AV.

Breast Cancer Res Treat. 2012 Feb;132(1):61-73. doi: 10.1007/s10549-011-1540-0. Epub 2011 May 4.

5.

Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer.

Creighton CJ, Fu X, Hennessy BT, Casa AJ, Zhang Y, Gonzalez-Angulo AM, Lluch A, Gray JW, Brown PH, Hilsenbeck SG, Osborne CK, Mills GB, Lee AV, Schiff R.

Breast Cancer Res. 2010;12(3):R40. doi: 10.1186/bcr2594. Epub 2010 Jun 22.

6.

Proteasome inhibition represses ERalpha gene expression in ER+ cells: a new link between proteasome activity and estrogen signaling in breast cancer.

Powers GL, Ellison-Zelski SJ, Casa AJ, Lee AV, Alarid ET.

Oncogene. 2010 Mar 11;29(10):1509-18. doi: 10.1038/onc.2009.434. Epub 2009 Nov 30.

7.

The type I insulin-like growth factor receptor pathway: a key player in cancer therapeutic resistance.

Casa AJ, Dearth RK, Litzenburger BC, Lee AV, Cui X.

Front Biosci. 2008 May 1;13:3273-87. Review.

PMID:
18508432

Supplemental Content

Support Center